AGENT-797 in Patients With Relapsed/Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose-escalation, single arm study to explore the safety,
tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT
cell therapy, in subjects with relapsed/refractory MM, as well as define the RP2D.